Clinical Trial Update: A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors [Phase 2]

View source ↗

Summary

Phase II trial investigating sacituzumab govitecan in advanced thymic epithelial tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma
• Thymoma

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Georgetown University | Conditions: Thymoma, Thymic Carcinoma | Phase 2 | Status: RECRUITING